ICAC 01 (ACE)

廉政公署 01 (ACE)

• 批准号: 7378882
• 负责人: Peyton A Eggleston
• 金额: $ 3.59万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378882
• 关键词: ICAC; 01; ACE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Over the past two decades, the prevalence of asthma has dramatically increased in many parts of the world. There is convincing evidence that children living in the inner cities of the United States, and living under economic disadvantages, constitute a unique and special at-risk population for asthma, which is characterized by increased morbidity and mortality (Akinbami et al, 2002; Cloutier et al, 2002). The recent update to the National Asthma Education and Prevention Program (NAEPP) asthma guidelines identified inhaled corticosteroids (ICS) as the preferred long-term control therapy for all forms of persistent asthma (National Asthma Education and Prevention Program Report, 2002). However, there is still a significant proportion of patients with persistent asthma who are not receiving ICS therapy or do not adhere to the treatment plan (Bauman et al, 2002). The guidelines will continue to change with further understanding of the pathogenesis of asthma, the introduction of new medications including immunomodulators, such as anti-IgE, and the potential application of biomarkers and pharmacogenetics in the clinical management of asthma. One of the additional measures of asthma control proposed in this study is the use of biomarkers, specifically the measurement of exhaled nitric oxide (eNO) using the Aerocrine NIOX device.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是中心的机构，不一定是研究者的机构。在过去的二十年里，哮喘的患病率在世界许多地区急剧增加。有令人信服的证据表明，生活在美国内城且生活在经济不利条件下的儿童​​构成了独特且特殊的哮喘高危人群，其特点是发病率和死亡率增加（Akinbami 等，2002；Cloutier等人，2002）。最近更新的国家哮喘教育和预防计划 (NAEPP) 哮喘指南将吸入皮质类固醇 (ICS) 确定为所有形式的持续性哮喘的首选长期控制疗法（国家哮喘教育和预防计划报告，2002 年）。然而，仍有很大比例的持续性哮喘患者没有接受ICS治疗或不遵守治疗计划（Bauman等，2002）。随着对哮喘发病机制的进一步了解、包括免疫调节剂（如抗 IgE）在内的新药物的引入，以及生物标志物和药物遗传学在哮喘临床管理中的潜在应用，该指南将继续发生变化。本研究中提出的哮喘控制的附加措施之一是使用生物标记物，特别是使用 Aerocrine NIOX 装置测量呼出一氧化氮 (eNO)。